EMA Authorised: Revolade (eltrombopag) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorized Revolade (eltrombopag). It covers idiopathic thrombocytopenic purpura and aplastic anaemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anaemia
• Idiopathic Thrombocytopenic Purpura

Drugs mentioned

• Revolade (eltrombopag)

Snippet

Status: Authorised. Therapeutic area: Purpura, Thrombocytopenic, Idiopathic;Anemia, Aplastic. MAH: Novartis Europharm Limited. Decision date: 15/01/2026